AdvanCell

Explore the latest insights on AdvanCell and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of AdvanCell’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Company Drug

InnoCare Doses First Patient in Registrational Phase III Head‑to‑Head Trial of Mesutoclax Versus Venetoclax – Challenging the Standard of Care in Treatment‑Naïve AML

InnoCare Pharma (HKG: 9969; SHA: 688428) announced today that the first patient has been dosed in the registrational Phase III head‑to‑head clinical trial of the Company's novel BCL2 inhibitor mesutoclax…

November 9, 2026

RonGu Biotechnology Completes Series A Financing of Nearly RMB 100 Million – Advancing Off‑the‑Shelf CAR‑NK and CAR‑T Therapies for Systemic Lupus Erythematosus

November 9, 2026

Eisai and Siemens Healthineers Sign Strategic Cooperation Agreement at CIIE – Advancing Precision Imaging in Alzheimer’s Disease Diagnosis and Treatment

November 9, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.

Explore Now

Company Deals

Eli Lilly Expands Collaboration with AdvanCell on Targeted Alpha Therapies for Cancer

February 12, 2025

AdvanCell

InnoCare Doses First Patient in Registrational Phase III Head‑to‑Head Trial of Mesutoclax Versus Venetoclax – Challenging the Standard of Care in Treatment‑Naïve AML

RonGu Biotechnology Completes Series A Financing of Nearly RMB 100 Million – Advancing Off‑the‑Shelf CAR‑NK and CAR‑T Therapies for Systemic Lupus Erythematosus

Eisai and Siemens Healthineers Sign Strategic Cooperation Agreement at CIIE – Advancing Precision Imaging in Alzheimer’s Disease Diagnosis and Treatment

Empowering Chinese Pharma’s Global Expansion

Eli Lilly Expands Collaboration with AdvanCell on Targeted Alpha Therapies for Cancer

About Company